Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $20.20 – a decrease of 3.95% over the previous week. Rigel Pharmaceuticals employs 162 staff and has a trailing 12-month revenue of around $179.3 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – RIGL.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Rigel Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Rigel Pharmaceuticals stock price (NASDAQ: RIGL)
Use our graph to track the performance of RIGL stocks over time.
Is it a good time to buy Rigel Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Rigel Pharmaceuticals price performance over time
Historical closes compared with the close of $20.2 from 2025-03-21
1 week (2025-03-14)
0.35%
1 month (2025-02-24)
-5.56%
3 months (2024-12-24)
22.87%
6 months (2024-09-24)
23.55%
1 year (2024-03-22)
1,322.54%
2 years (2023-03-23)
57.81%
3 years (2022-03-23)
30.9
5 years (2020-03-23)
41.26%
Is Rigel Pharmaceuticals stock undervalued or overvalued?
Valuing Rigel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Rigel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Rigel Pharmaceuticals's P/E ratio
Rigel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Rigel Pharmaceuticals shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Rigel Pharmaceuticals's EBITDA
Rigel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.4 million.
The EBITDA is a measure of a Rigel Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Rigel Pharmaceuticals financials
Revenue TTM
$179.3 million
Operating margin TTM
28.92%
Gross profit TTM
$137.3 million
Return on assets TTM
10.75%
Return on equity TTM
-699.05%
Profit margin
9.75%
Book value
$0.19
Market Capitalization
$363.9 million
TTM: trailing 12 months
Rigel Pharmaceuticals share dividends
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.
Have Rigel Pharmaceuticals's shares ever split?
Rigel Pharmaceuticals's shares were
split on a 1:10 basis on 26 June 2024
. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.
Rigel Pharmaceuticals share price volatility
Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $7.4843 up to $29.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.346. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rigel Pharmaceuticals overview
Rigel Pharmaceuticals, Inc. , a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc.
Frequently asked questions
What percentage of Rigel Pharmaceuticals is owned by insiders or institutions? Currently 2.84% of Rigel Pharmaceuticals shares are held by insiders and 68.529% by institutions.How many people work for Rigel Pharmaceuticals? Latest data suggests 162 work at Rigel Pharmaceuticals.When does the fiscal year end for Rigel Pharmaceuticals? Rigel Pharmaceuticals's fiscal year ends in December.Where is Rigel Pharmaceuticals based? Rigel Pharmaceuticals's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080What is Rigel Pharmaceuticals's ISIN number? Rigel Pharmaceuticals's international securities identification number is: US7665596034What is Rigel Pharmaceuticals's CUSIP number? Rigel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 766559108
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
